Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 1997

View Archived Issues

Hyalgan introduced in U.S. for osteoarthritis of the knee

First approval for irbesartan

Shire acquires Richwood

North American clinical trials with LiquiVent to be reinitiated

ArQule and GenQuest cancer collaboration

NDA for Colazide accepted for review by FDA

FDA clears new formulation of Imitrex

FDA requests additional manufacturing data before approval of Rituxan

Small peptides developed at Prolifix induce apoptosis in cancer cells

LU-51198 prevents complement-mediated myocardial injury

What's new in Cardiology? Highlights from the 19th Congress of the European Society of Cardiology

Famotidine for schizophrenia

Migraine prophylaxis with bisoprolol

Soluble TNF receptor may benefit patients with coronary artery disease

Cardiovascular benefits of the Mediterranean diet

Past, present and future of arrhythmia therapy

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....